Pharmaceutical News

RSS

Two-drug combination before surgery benefits women with triple-negative breast cancer

A breast cancer specialist and clinical researcher at Women & Infants Hospital of Rhode Island presented research yesterday at the 2014 San Antonio Breast Cancer Symposium showing that adding either the chemotherapy drug carboplatin or the blood vessel-targeting drug bevacizumab to the standard treatment of chemotherapy before surgery helped women who have the basal-like subtype of triple-negative breast cancer.

15 Dec 2014

Added benefit of aflibercept not proven in patients with diabetic macular oedema

Since August 2014, aflibercept (trade name Eylea) has been available also for patients with visual impairment due to diabetic macular oedema (DMO). The German Institute for Quality and Efficiency in Health Care examined in a dossier assessment whether this drug offers an added benefit over the appropriate comparator therapy.

15 Dec 2014

ANTRUK welcomes first report on antibiotic resistance; becomes BIA’s 2015 charity

Professor Colin Garner, Chief Executive of Antibiotic Research UK (ANTRUK), the world’s first charity to tackle the impending health disaster of antibiotic resistance, welcomed the publication of the first report by the O’Neill Commission on antibiotic resistance.

14 Dec 2014

Midazolam drug helps recover full consciousness in traumatic brain injury patient

A patient who had suffered a traumatic brain injury unexpectedly recovered full consciousness after the administration of midazolam, a mild depressant drug of the GABA A agonists family.

14 Dec 2014

Pharmacyclics receives BayBio's 2014 Pantheon DiNA Award for Outstanding Company

Pharmacyclics, Inc. today announced that it has been awarded BayBio's 2014 Pantheon DiNA Award for Outstanding Company for its rapid development and commercialization of IMBRUVICA (ibrutinib). The award was presented at BayBio's 11th Annual Pantheon DiNA Awards ceremony in San Francisco.

13 Dec 2014

FDA approves Fluzone Intradermal Quadrivalent vaccine to prevent four strains of influenza virus

Sanofi Pasteur, the vaccines division of Sanofi, today announced that the U.S. Food and Drug Administration has approved the supplemental biologics license application (sBLA) for Fluzone Intradermal Quadrivalent vaccine.

13 Dec 2014

New study investigates use of DNA barcoding to test authenticity of popular herbal supplements

Dr. Damon Little, Associate Curator of Bioinformatics in the Cullman Program for Molecular Systematics at The New York Botanical Garden, has just published a new study in the journal Genome investigating the use of DNA barcoding to test the authenticity of Ginkgo biloba (G. biloba), an herbal dietary supplement sold to consumers that is supposed to boost cognitive capacity.

12 Dec 2014

MD Anderson president applauds FDA's approval of new vaccine for HPV-related cancers

The Food and Drug Administration's approval of a new vaccine that targets five additional strains of human papilloma virus (HPV) fortifies a proven cancer-prevention weapon, according to Ronald A. DePinho, M.D., president of The University of Texas MD Anderson Cancer Center.

12 Dec 2014

Danish researchers working on new type of vaccine that targets disease causing bacterium

When we acquire diarrhea on a vacation, it is often caused by a bacterial infection. Now a Danish research team is working on a new type of vaccine design targeting the disease causing bacterium - if it works it may very well revolutionize not only the prevention of this disease, but also offer protection against other pathogens with a heavy disease burden such as Mycobacterium tuberculosis and antibiotic-resistant Staphylococcus aureus (MRSA).

12 Dec 2014

FDA clears ArmaGen's AGT-182 IND application for treatment of Hunter syndrome

ArmaGen, Inc., a privately held biotechnology company focused on developing novel therapies to treat severe neurological disorders, announced today that the Investigational New Drug (IND) application for the company's lead product candidate, AGT-182 for the treatment of Hunter syndrome, has been accepted by the U.S. Food and Drug Administration and is now active.

11 Dec 2014

Mylan announces U.S. launch of Prednisolone Sodium Phosphate Orally Disintegrating Tablets

Mylan Inc. today announced the U.S. launch of its Prednisolone Sodium Phosphate Orally Disintegrating Tablets, 10 mg, 15 mg, and 30 mg. This product is the first generic version of Shionogi's Orapred ODT.

11 Dec 2014

Mylan introduces Methocarbamol Injection USP, 100 mg/mL in the U.S.

Mylan Inc. today announced the U.S. launch of its Methocarbamol Injection USP, 100 mg/mL, packaged in 1,000 mg/10 mL single-dose vials. This product is the generic version of Hikma Maple Ltd.'s Robaxin.

11 Dec 2014

Scientists to explore effectiveness of tadalafil drug to tackle vascular dementia

Scientists are to explore whether drugs usually used to treat erectile problems by expanding blood vessels could become the next major way to tackle the dementia epidemic.

11 Dec 2014

Added benefit of daclatasvir drug not proven for chronic hepatitis C infection

The drug daclatasvir (trade name Daklinza) has been available since August 2014 for the treatment of adults with chronic hepatitis C (CHC) infection. The German Institute for Quality and Efficiency in Health Care examined in a dossier assessment whether this new drug offers an added benefit over the appropriate comparator therapy.

11 Dec 2014

New study reveals how COX-2 inhibitors can increase risk of heart attack in arthritis patients

A class of drug for treating arthritis - all but shelved over fears about side effects - may be given a new lease of life, following the discovery of a possible way to identify which patients should avoid using it.

11 Dec 2014

Prolongz drug achieves No. 1 spot in the personal care category

Prolongz, the all-natural FDA registered over-the-counter homeopathic drug that helps in the prevention of premature ejaculation, has been ranked No. 1 in the personal care category for July, August and September of 2014 by the Jordan Whitney Greensheet.

10 Dec 2014

Mylan announces U.S. launch of Celecoxib Capsules

Mylan Inc. today announced the U.S. launch of its Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg, one of the first available generic versions of Pfizer's Celebrex Capsules, which is indicated for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and for the management of acute pain in adults.

10 Dec 2014

Targeted therapy with radiopharmaceuticals has great potential for cancer treatment

Cancer therapy can be much more effective using a new way to customize nuclear medicine treatment, researchers say in the December 2014 issue of The Journal of Nuclear Medicine. The process could also be useful for other diseases that could benefit from targeted radiation.

10 Dec 2014

Study: Simeprevir-based therapy proves effective in treating chronic HCV infection

Researchers at Penn Medicine, in collaboration with a multi-center international team, have shown that a protease inhibitor, simeprevir, a once a day pill, along with interferon and ribavirin has proven as effective in treating chronic Hepatitis C virus infection (HCV) as telaprevir with interferon and ribavirin, the standard of care in developing countries.

10 Dec 2014

Drug proves effective at inhibiting growth of drug-resistant bacteria

A treatment pioneered at the University of Pittsburgh Center for Vaccine Research is far more effective than traditional antibiotics at inhibiting the growth of drug-resistant bacteria, including so-called "superbugs" resistant to almost all existing antibiotics, which plague hospitals and nursing homes.

10 Dec 2014

Pharmaceutical News

Two-drug combination before surgery benefits women with triple-negative breast cancer

Added benefit of aflibercept not proven in patients with diabetic macular oedema

ANTRUK welcomes first report on antibiotic resistance; becomes BIA’s 2015 charity

Midazolam drug helps recover full consciousness in traumatic brain injury patient

Pharmacyclics receives BayBio's 2014 Pantheon DiNA Award for Outstanding Company

FDA approves Fluzone Intradermal Quadrivalent vaccine to prevent four strains of influenza virus

New study investigates use of DNA barcoding to test authenticity of popular herbal supplements

MD Anderson president applauds FDA's approval of new vaccine for HPV-related cancers

Danish researchers working on new type of vaccine that targets disease causing bacterium

FDA clears ArmaGen's AGT-182 IND application for treatment of Hunter syndrome

Mylan announces U.S. launch of Prednisolone Sodium Phosphate Orally Disintegrating Tablets

Mylan introduces Methocarbamol Injection USP, 100 mg/mL in the U.S.

Scientists to explore effectiveness of tadalafil drug to tackle vascular dementia

Added benefit of daclatasvir drug not proven for chronic hepatitis C infection

New study reveals how COX-2 inhibitors can increase risk of heart attack in arthritis patients

Prolongz drug achieves No. 1 spot in the personal care category

Mylan announces U.S. launch of Celecoxib Capsules

Targeted therapy with radiopharmaceuticals has great potential for cancer treatment

Study: Simeprevir-based therapy proves effective in treating chronic HCV infection

Drug proves effective at inhibiting growth of drug-resistant bacteria

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Latest News